论文部分内容阅读
目的 :评估萘丁美酮对类风湿关节炎 (RA)的疗效和安全性。方法 :76例RA病人分 2组 ,萘丁美酮组 4 6例 ,男性 14例 ,女性 32例 ,年龄 4 5a±s 11a(2 2～ 68a) ,给萘丁美酮片 1g ,po ,qd× 4wk。双氯芬酸组 30例 ,男性 6例 ,女性 2 4例 ,年龄 4 4a± 10a(2 6～ 64a) ,给双氯芬酸 5 0mg ,po ,qd× 4wk。观察其临床疗效、实验室指标和不良反应。结果 :萘丁美酮组总有效率为 91% ,明显高于双氯芬酸组 (73% ,P <0 .0 5 ) ,2组治疗后临床各指标均有明显改善 (P <0 .0 1) ,萘丁美酮组不良反应为 15 % ,明显低于双氯芬酸组 (37% ,P <0 .0 5 )。结论 :萘丁美酮对RA具有良好疗效和较低的不良反应
Objective: To evaluate the efficacy and safety of nabumetone for rheumatoid arthritis (RA). Methods: A total of 76 patients with RA were divided into 2 groups, nabumetone group 46 cases, males 14 cases, females 32 cases, age 4 5a ± s 11a (2 2 ~ 68a) qd × 4wk. Diclofenac group of 30 patients, 6 males and 24 females, age 4 4a ± 10a (26 ~ 64a), diclofenac 50mg, po, qd × 4wk. Observe the clinical efficacy, laboratory indicators and adverse reactions. Results: The total effective rate of nabumetone group was 91%, which was significantly higher than that of diclofenac group (73%, P <0.05). The clinical indexes of two groups were significantly improved after treatment (P <0.01) , Nabumetone group adverse reaction was 15%, significantly lower than the diclofenac group (37%, P <0.05). Conclusion: Nabumetone has good curative effect and low adverse reaction to RA